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Maternal proteomic profiling 
reveals alterations in lipid 
metabolism in late‑onset fetal 
growth restriction
Cristina Paules1,2,6, Lina Youssef1,6, Jezid Miranda1, Francesca Crovetto1, 
Josep Maria Estanyol3, Guerau Fernandez4, Fatima Crispi1,5* & Eduard Gratacós1,5
Fetal growth restriction defined as the failure to achieve the fetal genetic growth potential is a major 
cause of perinatal morbidity and mortality. The role of maternal adaptations to placental insufficiency 
in this disorder is still not fully understood. We aimed to investigate the biological processes and 
protein–protein interactions involved in late‑onset fetal growth restriction in particular. We applied 2D 
nano LC–MS/MS proteomics analysis on maternal blood samples collected at the time of delivery from 
5 singleton pregnancies with late‑onset fetal growth restriction and 5 uncomplicated pregnancies. 
Data were analyzed using R package “limma” and Ingenuity Pathway Analysis. 25 proteins showed 
significant changes in their relative abundance in late‑onset fetal growth restriction (p value < 0.05). 
Direct protein–protein interactions network demonstrated that Neurogenic locus notch homolog 
protein 1 (NOTCH1) was the most significant putative upstream regulator of the observed profile. 
Gene ontology analysis of these proteins revealed the involvement of 14 canonical pathways. The 
most significant biological processes were efflux of cholesterol, efflux of phospholipids, adhesion 
of blood cells, fatty acid metabolism and dyslipidemia. Future studies are warranted to validate the 
potential role of the detected altered proteins as potential therapeutic targets in the late‑onset form 
of fetal growth restriction.
Fetal growth restriction (FGR) is one of the established pregnancy complications that involves fetal distress due 
to the failure in achieving the fetal genetic growth potential. FGR, usually defined as a birthweight less than 10th 
centile, affects 7–10% of pregnancies and implicates an increased risk of perinatal morbidity and  mortality1,2. 
This condition is also associated with cardiovascular, metabolic and neurodevelopmental changes in the off-
spring that persist into  adulthood3–5. Late-onset form of FGR, usually diagnosed after 32 weeks of gestation and 
delivered at  term6, is the most common clinical presentation of this condition encompassing more than 90% of 
FGR  cases7 and constituting a major contributing factor to adverse perinatal  outcome8. Placental dysfunction is 
the main culprit in FGR causing an impairment in the transfer of nutrients and oxygen from the mother to the 
developing  fetus9. Maternal adaptations to placental insufficiency may also play a role in the pathophysiology of 
 FGR10. Thus, exploring biological pathways in the maternal blood in pregnancies complicated by late-onset FGR 
may help in identifying the involved etiological mechanisms and detecting potential therapeutic targets for this 
disorder with the aim of preventing its short and long-term consequences.
Proteomic profiling exemplify the study of the global set of proteins in a particular  biosample11. Its application 
in pregnancy-related disorders has been implemented to improve the understanding of their  pathophysiology12. 
However, a handful number of previous studies have exploreed the maternal proteomic fingerprint of  FGR13–15. 
Moreover, none of them investigated separately late-onset FGR, indeed the studied population in the literature 
was principally formed by early-onset FGR cases since it’s the most severe phenotype. This approach carries a 
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certain bias given that late-onset FGR might have a different pathogenesis than its early-onset counterpart with 
similar long-term  consecuences7.
Our objective in this study was to focus on late-onset FGR and to analyze the maternal blood proteome in 
pregnancies complicated by this disorder compared to healthy pregnancies in order to determine the biological 
processes and protein–protein interactions involved in late-onset FGR.
Results
Clinical characteristics of the study population. Maternal baseline characteristics were similar 
between the study groups with the exception of lower maternal age in FGR cases compared to controls, as shown 
in Table 1. None of the patients included in our study suffered from chronic hypertension or pregestational 
diabetes. In addition, all of the pregnancies were conceived naturally without the use of assisted reproductive 
technologies. No differences were observed between the cases and the controls regarding feto-placental Doppler 
parameters. All the patients included in this study had normal feto-placental Doppler with the exception of one 
FGR case that presented abnormal cerebroplacental ratio.
In terms of perinatal outcomes, all the included gestations were delivered at term (> 37 weeks) with no dif-
ference between cases and controls (p = 0.24). In accordance with the study design, FGR newborns had signifi-
cantly lower birthweights (p = 0.01) with birthweight centiles < 3rd centile in all the cases (p = 0.01) compared to 
controls. No cases of perinatal mortality were observed in the study population.
Proteomics results. A total of 688 proteins were identified in our proteomics analysis, 25 proteins of them 
were differentially expressed (p value < 0.05) between cases and controls (Fig. 1). Out of these 25 proteins, 16 
were decreased in abundance and 9 were increased in FGR cases. The most highly modulated proteins were: 
(1) adiponectin (ADIPOQ), an adipocyte-specific protein, which plays a role in protecting against the develop-
ment of insulin resistance and  atherosclerosis16, p = 0.003; (2) lymphatic vessel endothelial hyaluronan receptor 
1 (LYVE1), an autocrine regulator of cell growth mediated by growth  regulators17, p = 0.005; (3) Lactotransferrin 
precursor (LTF), a stimulator of endothelial cell migration and proliferation which has a possible role in the 
regulation of bone  growth18, p = 0.010; (4) Galectin-7 (LGALS7), p = 0.010; (5) Phospholipid transfer protein 
(PLTP), p = 0.013. Some pregnancy specific beta-1-glycoproteins (specifically 2, 9 and 11) were also altered in 
late-onset FGR mothers, these proteins are mainly secreted by the placenta. In addition, our results uncover 
the high abundance of many lipoproteins in FGR mothers such as Apolipoprotein C2, Apolipoprotein C3 and 
Apolipoprotein E as well as fatty acid-binding protein 5. These lipoproteins play a pivotal role in the patho-
mechanisms of atherosclerosis by the regulation of triglyceride  levels19. Among the other proteins that are dif-
ferentially expressed in FGR galectin-3-binding protein, proteoglycan 4 and transgelin-2 which promote cell 
 adhesion20,21; epidermal growth factor receptor which may play a role in membrane ruffling and remodeling of 
the actin  cytoskeleton22; THAP domain-containing protein 4, platelet glyprotein Ib alpha chain and fibrinogen 
alpha chain which regulate endothelial cell proliferation and  hemostasis23; beta-defensin 103 that has an anti-
microbial activity; Di-N-acetylchitobiase, involved in the degradation of asparagine-linked glycoproteins and 
Table 1.  Baseline characteristics and perinatal outcomes of the study populations. Data are shown as median 
(interquartile range) or percentages as appropriate. p value was calculated by Mann Whitney U test and Fisher 
exact test for continuous and categorical variables respectively.
Uncomplicated pregnancies (n = 5) Fetal growth restriction (n = 5) p value
Baseline characteristics
Age (years) 31 (28 to 31) 26.5 (24.5 to 28) 0.05
Caucasian (%) 74 100 0.24
Nulliparity (%) 40 40 1
Smoking (%) 0 20 0.29
Feto-placental Doppler before delivery
Uterine arteries mean pulsatility index (z score) − 0.27 (− 2.19 to 1.25) 0.14 (− 0.35 to 2.47) 0.65
Umbilical artery pulsatility index (z score) 0.16 (− 0.4 to 0.88) 0.66 (− 0.14 to 1.35) 0.65
Middle cerebral artery pulsatility index (z score) − 0.33 (− 0.4 to 0.51) 0.25 (− 0.47 to 0.46) 1
Cerebroplacental ratio (z score) − 0.02 (− 1.32 to 0.49) − 1.05 (− 1.49 to − 1) 0.46
Perinatal outcomes
Gestational age at delivery (weeks) 39 (38 to 39) 37 (37 to 38) 0.24
Birthweight (gr) 3276 (3030 to 3670) 1980 (1980 to 2420) 0.01
Birthweight centile 42 (41 to 55) 0 (0 to 2) 0.01
Male gender (%) 40 60 0.53
Cesarean section (%) 20 0 0.29
APGAR score 5 min < 7 0 (0) 0 (0) 1
Umbilical cord artery pH 7.28 (7.25 to 7.35) 7.11 (7.11 to 7.12) 0.01
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other degradational proteins like ATP synthase subunit g, mitochondrial and Olfactomedin-like-protein 2B. 
Individual values of the 25 differentially expressed proteins are displayed in Supplementary Table S1.
Protein–protein interaction network. Direct protein–protein interactions among the different com-
ponents of the network were established by the Ingenuity database (Fig. 2). Neurogenic locus notch homolog 
protein 1 (NOTCH1) that showed up in this network was highlighted as the most significant putative upstream 
regulator, meaning that NOTCH1 could be a key regulator of the observed profile. Other proteins such as Signal 
transducer and activator of transcription 3 (STAT3), Estrogen receptor 1 (ESR1) or ATP-binding cassette sub-
family G member 2 (ABCG2) show also many important interactions.
Biological processes involved. Gene ontology analysis of the corresponding proteins that were statisti-
cally different in FGR revealed the involvement of 14 canonical pathways, the top 5 canonical pathways canoni-
cal pathways are shown in Table 2. We further studied the potential mechanisms and identified 500 biological 
processes related to FGR. The most significant biological processes were efflux of cholesterol, efflux of phospho-
lipids, adhesion of blood cells, fatty acid metabolism and dyslipidemia. Most of the top 25 biological processes 
displayed in Table 3 were related to lipid metabolism or hemostasis.
Discussion
This is the first study that focuses on maternal proteomic profile in pregnancies complicated by the late-onset 
form of FGR. The results of the present study elucidate that lipid metabolism is disturbed in mothers from preg-
nancies complicated by late-onset FGR compared to healthy pregnancies. Furthermore, our results indicate that 
NOTCH1 could be an important regulator of the observed profile.
The findings of our study demonstrate that late-onset FGR has a proteomic signature in maternal plasma 
similarly to the previous observations that focused on the early-onset form of this  disorder15 or mixed up early 
and late-onset  cases13,14. A vast majority of the identified proteins and biological processes are related to lipid 
metabolism which is in line with prior  studies10,24,25. Among the differentially expressed proteins in late-onset 
FGR, the highest magnitude of change was observed in Adiponectin that was underexpressed in FGR mothers. 
This observation might reflect a failure in the physiological response to pregnancy demands since Adiponectin 
concentrations are usually elevated in healthy pregnancies due to pregnancy related “Adiponectin resistance”26.
In light of the protein–protein interactions observed in late-onset FGR, we can hypothesize that different 
biological processes related to lipid metabolism and homeostasis have an impact on other regulator proteins. 
These proteins may play an essential role in the pathogenesis of late-onset FGR due to their close relationship 
Figure 1.  Differentially expressed proteins in late-onset fetal growth restriction. ADIPOQ adiponectin, APOC2 
apolipoprotein C-II, APOC3 apolipoprotein C-III, APOE apolipoprotein E, ATP5L ATP synthase subunit g 
mitochondrial, CTBS Di-N-acetylchitobiase, DEFB103A beta-defensin 103, EGFR epidermal growth factor 
receptor, FABP5 fatty acid-binding protein 5, FGA fibrinogen alpha chain, GP1BA platelet glyprotein Ib alpha 
chain, LGALS3BP galectin-3-binding protein, LGALS7 galectin-7, LTF lactotransferrin precursor, LYVE1 
lymphatic vessel endothelial hyaluronan receptor 1, OLFML2B olfactomedin-like-protein 2B, P01815 unknown 
protein, P04220 unknown protein, PLTP phospholipid transfer protein, PRG4 proteoglycan 4, PSG2 pregnancy 
specific beta-1-glycoprotein 2 PSG9 pregnancy-specific beta-1-glyprotein 9, PSG11 pregnancy-specific beta-1-
glyprotein 11, TAGLN2 Transgelin-2, THAP4 THAP domain-containing protein 4.
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with the development of the extravillous trophoblast lineage in the human placenta (NOTCH1)27, the regulation 
of trophoblast invasion and the expression and activity of placental amino acid transporters (STAT3)28 or the 
differentiation of estrogen-dependent cells (ESR)29. Indeed, previous studies have demonstrated alterations in the 
immunoreactivity and localization of NOTCH proteins as well as decreased STAT3 in placentas from pregnancies 
complicated by FGR suggesting a contribution of these disruptions in trophoblast differentiation and  function30,31. 
In the present study, NOTCH1 was the most featured regulator in the spotted network linking the disturbed 
profile of lipid metabolism with placental growth and being a potential target for future therapeutic agents.
Furthermore, our gene ontology analysis has revealed that the top canonical pathways and biological processes 
involved in late-onset FGR are mostly related to the efflux of cholesterol and phospholipids. Indeed, multiple 
Figure 2.  Network analysis combining focused proteins (colored) that correspond to differentially expressed 
proteins in late-onset fetal growth restriction (green: underexpressed, red: overexpressed) and non-focused 
proteins that were added by Ingenuity, using knowledge derived data from their own database. ABCG2 
ATP-binding cassette sub-family G member 2, ADIPOQ Adiponectin, APOC2 apolipoprotein C-II, APOC3 
apolipoprotein C-III, APOE apolipoprotein E, BCL2 B-cell lymphoma 2, CD209 cluster of differentiation 209, 
CHKA choline kinase alpha, CRYAB alpha-crystallin B chain, CTBS Di-N-acetylchitobiase, EGF epidermal 
growth factor, EGFR epidermal growth factor receptor, ENAH protein enabled homolog, ESR1 estrogen receptor 
1, FABP5 fatty acid-binding protein 5, GP1BA platelet glyprotein Ib alpha chain, GPER1 G-protein coupled 
estrogen receptor 1, LGALS3BP galectin-3-binding protein, LGALS7 galectin-7, LTF lactotransferrin, LYVE1 
lymphatic vessel endothelial hyaluronan receptor 1, NOTCH1 neurogenic locus notch homolog protein 1, P85 
(pirk3r) phosphatidylinositol 3-kinase, PGR progesterone receptor, PLTP Phospholipid transfer protein, PPARG 
peroxisome proliferator-activated receptor gamma, PSG9 pregnancy-specific beta-1-glyprotein 9, PTPN9 
protein tyrosine phosphatase, non-receptor type 9, PTPRK protein tyrosine phosphatase receptor type K, RARA 
retinoic acid receptor alpha, SAA serum amyloid A, SDCBP syndecan binding protein, STAT3 signal transducer 
and activator of transcription 3, TAGLN2 transgelin-2, TP53 tumor protein p53.
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pathways share similar identified molecules where the lipoproteins Apolipoprotein C2, Apolipoprotein C3 and 
Apolipoprotein E are central. Thus, co-activation of parallel pathways seems to have occurred in FGR mothers. 
The most significant pathway was LXR/RXR activation, a fundamental pathway in the balance of cholesterol 
 levels18 and known to have a protective function against dysregulated fetoplacental lipid  homeostasis32. In addi-
tion, FXR/RXR activation and LPS/IL-1 Mediated Inhibition of RXR Function were also initiated, which might 
affect several functions since FXR is a metabolic regulator and cell protector against oxidative  stress33. The same 
lipoproteins are involved in atherosclerosis and IL-12 signaling replicating the link between inflammation, lipid 
dysregulation and endothelial cell dysfunction. In fact, oxidative stress, inflammation and placental thrombosis 
are likely to interrupt the placental ability to transfer the necessary nutrients and oxygen to the fetus and therefore 
impede the normal fetal  growth34–37.
The current study focused on the late-onset form of this disorder revealing specific pathways and key player 
proteins that can provide further insights into the pathophysiology of late-onset FGR. In fact, lipid metabolism 
Table 2.  Top 5 canonical pathways involved in late-onset fetal growth restriction. APOC2 Apolipoprotein C2, 
APOC3 Apolipoprotein C3, APOE Apolipoprotein E, FABP5 Fatty acid-binding protein 5, FGA Fibrinogen 
alpha chain, FXR Farsenoid X receptor, IL-1 Interleukin-1, IL-12 Interleukin-12, LPS Lipopolysaccharide, LXR 
Liver X receptor, PLTP Phospholipid transfer protein, RXR Retinoid X receptor.
Canonical pathways p value Molecules
LXR/RXR Activation 2.17E−07 APOE, APOC2, PLTP, FGA, APOC3
FXR/RXR Activation 2.56E−07 APOE, APOC2, PLTP, FGA, APOC3
LPS/IL-1 Mediated Inhibition of RXR Function 8.29E−05 APOE, APOC2, PLTP, FABP5
Atherosclerosis Signaling 3.66E−04 APOE, APOC2, APOC3
IL-12 Signaling and Production in Macrophages 5.67E−04 APOE, APOC2, APOC3
Table 3.  Top 25 biological processes involved in late-onset fetal growth restriction. ADIPOQ Adiponectin, 
APOC2 Apolipoprotein C-II, APOC3 Apolipoprotein C-III, APOE Apolipoprotein E, EGFR Epidermal growth 
factor receptor, FABP5 Fatty acid-binding protein 5, FGA Fibrinogen alpha chain, GP1BA Platelet glyprotein 
Ib alpha chain, LGALS3BP Galectin-3-binding protein, LTF Lactotransferrin precursor, LYVE1 Lymphatic 
vessel endothelial hyaluronan receptor 1, PLTP Phospholipid transfer protein, PSG2 Pregnancy specific beta-1-
glycoprotein 2.
Diseases or Functions Annotation p value Molecules
Efflux of cholesterol 4.80E−09 ADIPOQ, APOC2, APOC3, APOE, PLTP
Efflux of phospholipid 4.89E−09 APOC2, APOC3, APOE, PLTP
Adhesion of blood cells 1.96E−07 ADIPOQ, APOE, FGA, GP1BA, LTF, PLTP
Fatty acid metabolism 2.02E−07 ADIPOQ, APOC2, APOC3, APOE, EGFR, LTF, PLTP
Dyslipidemia 1.55E−06 ADIPOQ, APOC2, APOC3, APOE
Adhesion of immune cells 2.49E−06 ADIPOQ, APOE, FGA, LTF, PLTP
Synthesis of fatty acid 2.62E−06 APOC2, APOC3, APOE, EGFR, LTF
Binding of cells 2.77E−06 ADIPOQ, APOE, EGFR, GP1BA, LGALS3BP, LTF
Cell movement of hepatoma cell lines 4.84E−06 ADIPOQ, EGFR, LYVE1, TAGLN2
Concentration of lipid 6.24E−06 ADIPOQ, APOC3, APOE, EGFR, PLTP
Binding of blood cells 1.40E−05 ADIPOQ, APOE, GP1BA, LTF
Adhesion of lymphoma cell lines 1.66E−05 APOE, EGFR, FGA
Homeostasis of lipid 1,90E−05 APOC2, APOC3, APOE
Adhesion of tumor cell lines 3.28E−05 APOE, EGFR, FGA, GP1BA, LTF
Progression of digestive organ tumor 3.47E−05 APOE, EGFR
Progression of carcinoma 4.46E−05 APOE, EGFR
Binding of myeloid cells 4.68E−05 ADIPOQ, APOE, LTF
Aggregation of cells 4.83E−05 EGFR, FGA, GP1BA, PSG2
Hyperlipidemia 5.39E−05 APOC2, APOC3, APOE
Binding of macrophages 6.80E−05 ADIPOQ, APOE
Fibrinolysis 8.16E−05 FGA, GP1BA
Lower respiratory tract disorder 9.59E−05 EGFR, FABP5, LTF, PLTP
Fibrin clot 9.64E−05 FGA, GP1BA
Homeostasis of triacylglycerol 9.64E−05 APOC2, APOC3
Binding of fibroblasts 1.12E−04 APOE, LGALS3BP
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during the normal pregnancy is essential to provide the necessary fatty acids for fetal  growth38. It is widely 
accepted that placental insufficiency is the main culprit in FGR resulting from shallow trophoblast invasion 
during the early stages of  gestation7. Indeed, many placental enzymes involved in the supply of fatty acids to 
the growing fetus, like endothelial lipase and lipoprotein lipase, have been described to be dysregulated in FGR 
 pregnancies39. Thus, it seems plausible that maternal poor response to pregnancy demands of lipids and fatty 
acids may contribute to the placental dysfunction and suboptimal fetal growth. In addition, we observed a favored 
proinflammatory status in the studied cases of late-onset FGR supporting the existence of an inflammatory bias 
in this  disorder40.
This study has some strengths and limitations that merit a comment. All the pregnancies included in this study 
were recruited prospectively, well selected and characterized to constitute homogenous groups of late-onset FGR 
cases and controls. Cases and controls were matched by gestational age at maternal blood sampling. Moreover, 
this was a comprehensive proteomics study not only revealing the different proteins in late-onset FGR but also 
the protein–protein interactions and the involved biological processes. The center of our analysis was to identify 
the pathophysiological pathways that may play a role in this form of FGR, thus we opted for a wider look at the 
results without applying a statistical correction for multiple comparisons. On the other hand, we acknowledge 
the small sample size of our study and the importance of future validation of our findings in larger cohorts.
In conclusion, the present study indicates that lipid metabolism dysregulation plays a vital role in pregnancies 
complicated by late-onset FGR. Importantly, our findings highlight the central regulator of the observed profile 
being NOTCH1. These results enhance our understanding of the pathophysiology of late-onset FGR which 
remains poorly defined. Furthermore, they may constitute a starting point for future studies to investigate the 
potential therapeutic targets of the involved pathways.
Methods
Study design. We conducted a prospective case–control study in the Departments of Maternal–Fetal Medi-
cine at BCNatal (Barcelona, Spain) between July and October 2016. The study population included 5 singleton 
pregnancies diagnosed with late-onset FGR which was defined as an estimated fetal weight and birthweight 
below the 10th  centile2. Late-onset refers to delivery occurring after 37 weeks of gestation. Uncomplicated preg-
nancies with appropriate fetal growth for gestational age-defined as estimated fetal weight and birthweight above 
the 10th centile were randomly selected from our general population to be included as controls and frequency 
paired with cases by gestational age at maternal blood sampling (± 2 weeks). In all pregnancies, gestational age 
was calculated based on crown–rump length measurement on first-trimester  ultrasound41 and weight centiles 
were assigned according to local  standards42. Pregnancies with congenital malformations, chromosomal abnor-
malities or intrauterine infection were excluded. The study was conducted in accordance with the principles of 
the Helsinki declaration. The study protocol has been approved by the local ethics committee (Comité Ético 
de Investigación Clinica, Hospital Clinic, Barcelona) number HCB/2016/0253. Participating patients provided 
their written informed consent.
Data collection and study protocol. The following data were recorded upon enrollment: maternal age, 
ethnicity, known chronic disease (i.e. hypertension, diabetes mellitus), parity, obstetric history, mode of concep-
tion and smoking status. Feto-placental Doppler parameters were obtained in the last 2 weeks of pregnancy, 
including the uterine  arteries43, the umbilical  artery44, and the fetal middle cerebral artery pulsatility  indices44, 
with the calculation of the cerebroplacental  ratio45. These values were normalized into z scores accordingly and 
considered abnormal if > 95th centile for uterine arteries mean and umbilical artery pulsatility indices and < 5th 
centile for the middle cerebral artery pulsatiliy index and the cerebroplacental  ratio43–45. At the time of delivery, 
gestational age, birthweight, birthweight centile, Apgar scores, umbilical artery pH and perinatal mortality were 
recorded. In addition, maternal blood samples were collected for subsequent proteomic analysis.
Maternal blood sampling. Maternal blood samples were drawn from peripheral veins within 2 h after 
delivery and collected in EDTA-treated tubes. Plasma was separated by centrifugation at 1500g for 10 min at 
4 °C, and samples were immediately stored at − 80 °C until analyzed.
Proteomics technique. Before proteomic analysis, the depletion of fourteen highly and medium abun-
dant proteins was performed using Seppro IgY14 and Seppro SuperMix columns following the manufacturer’s 
instructions. Afterwards, samples were processed for tandem mass tag (TMT) before acquisition on a nanoscale 
liquid chromatography coupled to tandem mass spectrometry (2D nano LC–MS/MS) analysis from Thermo 
Fisher. Protein identification/quantification was performed on Proteome Discoverer software v.1.4.0.288 
(Thermo Fisher) by Multidimensional Protein Identification Technology. On initial proteomic analysis, readers 
were blinded to each patient’s status. Detailed methodology is provided as supplementary information.
Statistical analysis. Clinical characteristics of the study population were summarized as median (inter-
quartile range) or percentages for continuous and categorical variables respectively. The analysis was performed 
using STATA 14.2 (StataCorp LLC, Texas, USA) including the use of Mann Whitney U test and Fisher exact 
test for continuous and categorical variables respectively. All reported p values are two-sided. Differences were 
considered significant when p < 0.05.
For proteomics data, differentially expressed proteins were determined using R package “limma”46. Data were 
preprocessed, normalized and a moderated t-test was applied (p < 0.05). Network analysis was generated through 
the use of QIAGEN’s Ingenuity Pathway Analysis (IPA), QIAGEN Inc., (https ://www.qiage nbioi nform atics .com/
produ cts/ingen uity-pathw ay-analy sis). Networks combined focused proteins that correspond to differentially 
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expressed proteins which were detected by “limma” analysis and non-focused proteins that were added by IPA, 
using knowledge derived data from their own database. To gain a further insight into the potential mechanisms 
involved, the identified proteins were mapped to IPA database.
Data availability
The proteomics quantification data reported in this study are available as supplementary information.
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